Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids
Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids, a Double Blind Placebo Controlled Randomized Pilot Study
Sponsor: Mayo Clinic
Listed as NCT01733147, this PHASE4 trial focuses on Barrett's Esophagus and Obesity and remains completed. Sponsored by Mayo Clinic, it has been updated 11 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Mar 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE4
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE4
▶ Show 6 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE4
-
Dec 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE4
-
Feb 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .